Most guides to addiction treatment Cozumel programs are written for the patient. This one is for the person sitting next to them on the flight: the partner, parent, sibling or friend who agreed to come along. Companions carry a quiet, important job in a physician-supervised ibogaine program, and nobody hands them a manual. Consider this the manual.
It covers what to learn before you travel, what your role is on treatment day and the day after, how 5-MeO-DMT fits later in the week, and what to watch for once you are both home. It also says plainly what you cannot do, because a companion who understands the limits of their role is far more useful than one who thinks they are the safety net.
Start with the hardest fact, because the patient may not want to hear it twice. People have died during and after ibogaine treatment, in clinics as well as outside them. Heart rhythm problems are the suspected cause in many of those deaths. Any program that will not say this to you directly is not one to travel to.
Why do addiction treatment Cozumel programs ask for a companion?
Ibogaine is a long, physically heavy experience, and the days after it are not days to be alone. The patient will be exhausted, unsteady and emotionally raw. Staff handle the medical side; a companion handles the human side, from fetching water to simply being a familiar face when the visions fade.
There is a second reason. Companions see the patient before and after the clinic does. You know what a normal week looks like for them, which means you are the person most likely to notice when something after treatment is not normal. Programs that take the risks seriously treat the companion as part of the plan, and will brief you accordingly. Our ibogaine retreats page describes the program formats so you can see where a companion fits in each.
Cozumel itself makes the job easier in small ways. The island is quiet, the sea is close, and the pace is slow. It is reached by a short flight into its own airport or by ferry from Playa del Carmen, and the time difference from the eastern United States is small. But the setting never replaces the screening, and the medicine carries the same risks here as anywhere.
What should a companion know before the trip?
Sit in on the screening calls if the patient allows it. Screening should cover a full medical history, a current electrocardiogram (ECG) and bloodwork including potassium and magnesium. Ask whether those electrolytes are checked and corrected before dosing, and again after vomiting, since ibogaine commonly causes vomiting and low levels add to the rhythm risk. Magnesium is a reasonable precaution, not proven protection; no study has shown it prevents arrhythmia.
Medications are where companions often know more than the clinic. Some antidepressants block the enzyme that clears ibogaine and need weeks to wash out, not days. Stopping one has its own risks and is done only with the prescriber who prescribed it, never quietly in the weeks before a flight. Ibogaine is cleared by a liver enzyme that varies from person to person, which is why some medicines raise its level.
Heavy drinking or daily benzodiazepine use must be stabilised first. Withdrawal seizures appear in the ibogaine fatality reports, and a careful team will postpone instead of dosing through it. If the patient takes methadone or buprenorphine, any change before dosing is handled by the treating clinic's physicians where the treatment takes place, not at home. Stopping either carries its own overdose risk, so it is never done alone.
Ask, with the patient, how many days before dosing each must stop, what they take in the meantime, and how the clinic confirms buprenorphine has cleared; a long-acting monthly injection can stay detectable for a year or more, and routine urine screens can miss it. Never let anyone bridge with opioids from another source. A pill or powder bought outside a pharmacy can contain far stronger opioids than it claims.
Finally, ask the clinic how far the nearest hospital with emergency cardiac care is and how a transfer works on the island. You want to hear that plan described, not assumed.
What does the companion do on treatment day and the day after?
Less than you might expect, and more than you might like. Ibogaine is given under continuous heart monitoring with a physician present. You are not the monitor, the nurse or the doctor, and you should not try to be. Your job is to stay reachable, rest while you can, and be ready for the long tail of the experience.
Understand what monitoring is and is not. Monitored hospital patients have reached dangerous QT intervals. Monitoring can catch a dangerous rhythm early enough to treat it; it does not prevent one and can miss one. That is why you should know who is in the room overnight, what their training is, and what emergency drugs and equipment are on hand. Asking is not rude. It is the job.
The patient will need help walking for at least a day, including to the bathroom, and staff should be doing that lifting. The day after, often called the grey day, brings fatigue, flat mood and a busy mind. Expect tears, silence or a flood of talking, and do not try to fix any of it.
Learn the emergency signs now, not later: fainting, a racing or irregular heartbeat, or a seizure. Each is an emergency at any time, and the risk lasts at least the first week and until an ECG is normal. The QT interval commonly stays long past the first day, and in reported cases for more than a week. If you see any of those signs, call staff immediately, and emergency services if you are already home.
How should a companion think about 5-MeO-DMT later in the week?
Some programs offer 5-MeO-DMT once the body has recovered from ibogaine. Many people know it as bufo, the secretion of the Sonoran desert toad, or search for it as the bufo drug. It is short-acting, usually inhaled, and very different in character from ibogaine. Human clinical safety evidence for 5-MeO-DMT is still limited and short-term.
One rule matters above all others. 5-MeO-DMT must never be combined with MAO inhibitors, including ayahuasca, other harmala preparations and MAOI antidepressants, because that combination can be fatal. An MAOI antidepressant can keep acting after its last dose, so stopping one shortly before a session does not remove the danger, and stopping any antidepressant is done only with the prescriber who prescribed it. Make sure both that prescriber and the clinic's physician know about any MAOI, ayahuasca or harmala preparation the patient has used.
5-MeO-DMT can briefly raise blood pressure, so high blood pressure and heart disease belong in the screening for it. No published study establishes a safe interval between ibogaine and 5-MeO-DMT, and the human data are too thin to say how much screening and an experienced sitter change the risk. The physician's judgement, the patient's ECG and how they feel decide whether a session happens, not the calendar. A companion's role here is to make sure nothing is hidden from the medical team.
What does the companion watch for after going home?
Travel follows a normal ECG, not a set number of days. Until that ECG is normal, no new medicine is started, anti-nausea drugs included, without asking a prescriber who knows about the ibogaine whether it affects the QT interval. Keep a copy of the discharge ECG and a written summary of what was given and when; any clinician at home needs to see it before prescribing anything.
If opioids were part of the patient's history, this is the paragraph to memorise. After ibogaine, opioid tolerance falls by an amount no one can predict, so a dose they used before can be a fatal overdose. Opioids may also act more strongly than expected. Leave with naloxone, learn how to use it yourself, make sure others in the household can too, and call emergency services in any suspected overdose. Settle with the treating physician before leaving whether and when methadone or buprenorphine restarts and who would do it; methadone for addiction normally comes only from a certified program, and it prolongs the QT interval.
Then comes the slower work. Ask what aftercare contact looks like in the first month and who the patient will actually speak to. Watch for the ordinary signs of a hard week: sleep falling apart, isolation, old contacts resurfacing. You are not responsible for their choices, but you are well placed to say what you see.
How do companions look after themselves?
Companions often arrive braced for a crisis and leave with a strange mix of relief and depletion. Plan for it. Use the quiet days on the island to walk, swim and sleep instead of hovering. Eat properly. Tell a friend at home what you are doing so someone is looking after you too.
Be clear-eyed about what treatment can and cannot do. Ibogaine programs draw people with opioid, stimulant, alcohol and kratom histories, and people whose main concern is trauma or depression. For trauma, the evidence comes from small studies without a comparison group. For addiction, the research is mostly observational. No program can promise an outcome, and a companion who expects one is setting both people up for a fall.
Know the legal ground too. Mexico has not scheduled ibogaine, so it is unregulated there, not approved. A clinic can hold a health establishment license, and that is not an approval of ibogaine. Ibogaine and 5-MeO-DMT are both Schedule I in the United States. None of that is a reason to stay silent; it is the reason to ask hard questions before you both board the plane.
If you are weighing addiction treatment Cozumel programs with someone you love, ask the clinic to brief you as a companion before any booking is made. MindScape Retreat will walk both of you through the screening, the risks in the patient's case, and what your role would be from arrival to the weeks after you return. If you are in crisis in the United States, call or text 988.
Begin Your Journey
MindScape Retreat offers medically supervised ibogaine treatment in Cozumel, Mexico. Speak with our clinical team to learn if you are a candidate.


